Ajer leaving BioMarin as head of commercial

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said in an SEC filing that EVP and Chief Commercial Officer (CCO) Jeffrey Ajer will be terminated “without cause,” effective July 1. Ajer has worked at BioMarin since 2005, and held several roles before becoming SVP, CCO in 2012. No successor was announced. The move comes a few weeks after the biotech settled with activist investor Elliott Investment Management, with the company agreeing to expand its board and review its strategy and operations.

mRNA therapeutics company Eleven Therapeutics Ltd. hired Paloma Giangrande as CTO. Giangrande was VP of platform and discovery at Wave Life Sciences Ltd. (NASDAQ:WVE), and director of rare diseases at Moderna Inc. (NASDAQ:MRNA)...